Targeted 13C-labeled tracer fate associations for drug efficacy testing in cancer

László G. Boros, Richard D. Beger, Emmanuelle J. Meuillet, Jerry R. Colca, Sándor Szalma, Patricia A. Thompson, L. Dux, Gyula Farkas, Gábor Somlyai

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Metabolomics technologies continue to develop not only to study endpoint steady-state concentrations of numerous metabolites in normal and cancer cells but also to examine metabolic flux and networks. These techniques are of importance for understanding tumor cell metabolism and for the development of new drugs and treatment strategies. The choice of tracer substrates is central as 13C-labeled substrates readily improve real-time reaction visibility by increasing metabolic network transparencies in cancer metabolomics. In this chapter, targeted [1,2- 13C2]-d-glucose single tracer fate associations are compared with the external [U- 13C18]-stearate oxidation model for thiazolidinedione efficacy testing in primary liver tumor cells. Although the externally supplied [U- 13C18]-stearate tracer readily labels multiple products by acetyl-CoA exchange, parallel stearate synthesis and mobilization from unlabeled intracellular pools disrupt its uptake after drug treatment. This can be overcome by using cross-labeled 13C-stearate from [1,2- 13C2]-d-glucose as the internal tracer and the independent explanatory variable to study associations among markers of rosiglitazone-induced stearate breakdown in a single [1,2-13C2]-d-glucose tracer experiment during drug efficacy testing in cultured cells.

Original languageEnglish
Title of host publicationTumor Cell Metabolism: Pathways, Regulation and Biology
PublisherSpringer-Verlag Vienna
Pages349-372
Number of pages24
ISBN (Print)9783709118245, 9783709118238
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Stearates
Cells
Testing
Metabolomics
Pharmaceutical Preparations
rosiglitazone
Neoplasms
Metabolic Networks and Pathways
Glucose
Tumors
Drug therapy
Acetyl Coenzyme A
Substrates
Metabolites
Metabolism
Visibility
Liver
Transparency
Labels
Cultured Cells

Keywords

  • 2-13C2]-d-Glucose [U-13C18]-stearate
  • EZTopolome [1
  • Liver cancer
  • SWAS
  • System-wide association study
  • Targeted tracer fate association study
  • TTFAS

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Boros, L. G., Beger, R. D., Meuillet, E. J., Colca, J. R., Szalma, S., Thompson, P. A., ... Somlyai, G. (2015). Targeted 13C-labeled tracer fate associations for drug efficacy testing in cancer. In Tumor Cell Metabolism: Pathways, Regulation and Biology (pp. 349-372). Springer-Verlag Vienna. https://doi.org/10.1007/978-3-7091-1824-5_15

Targeted 13C-labeled tracer fate associations for drug efficacy testing in cancer. / Boros, László G.; Beger, Richard D.; Meuillet, Emmanuelle J.; Colca, Jerry R.; Szalma, Sándor; Thompson, Patricia A.; Dux, L.; Farkas, Gyula; Somlyai, Gábor.

Tumor Cell Metabolism: Pathways, Regulation and Biology. Springer-Verlag Vienna, 2015. p. 349-372.

Research output: Chapter in Book/Report/Conference proceedingChapter

Boros, LG, Beger, RD, Meuillet, EJ, Colca, JR, Szalma, S, Thompson, PA, Dux, L, Farkas, G & Somlyai, G 2015, Targeted 13C-labeled tracer fate associations for drug efficacy testing in cancer. in Tumor Cell Metabolism: Pathways, Regulation and Biology. Springer-Verlag Vienna, pp. 349-372. https://doi.org/10.1007/978-3-7091-1824-5_15
Boros LG, Beger RD, Meuillet EJ, Colca JR, Szalma S, Thompson PA et al. Targeted 13C-labeled tracer fate associations for drug efficacy testing in cancer. In Tumor Cell Metabolism: Pathways, Regulation and Biology. Springer-Verlag Vienna. 2015. p. 349-372 https://doi.org/10.1007/978-3-7091-1824-5_15
Boros, László G. ; Beger, Richard D. ; Meuillet, Emmanuelle J. ; Colca, Jerry R. ; Szalma, Sándor ; Thompson, Patricia A. ; Dux, L. ; Farkas, Gyula ; Somlyai, Gábor. / Targeted 13C-labeled tracer fate associations for drug efficacy testing in cancer. Tumor Cell Metabolism: Pathways, Regulation and Biology. Springer-Verlag Vienna, 2015. pp. 349-372
@inbook{be6f048ff8b145fbaeb7fd9e56162fb5,
title = "Targeted 13C-labeled tracer fate associations for drug efficacy testing in cancer",
abstract = "Metabolomics technologies continue to develop not only to study endpoint steady-state concentrations of numerous metabolites in normal and cancer cells but also to examine metabolic flux and networks. These techniques are of importance for understanding tumor cell metabolism and for the development of new drugs and treatment strategies. The choice of tracer substrates is central as 13C-labeled substrates readily improve real-time reaction visibility by increasing metabolic network transparencies in cancer metabolomics. In this chapter, targeted [1,2- 13C2]-d-glucose single tracer fate associations are compared with the external [U- 13C18]-stearate oxidation model for thiazolidinedione efficacy testing in primary liver tumor cells. Although the externally supplied [U- 13C18]-stearate tracer readily labels multiple products by acetyl-CoA exchange, parallel stearate synthesis and mobilization from unlabeled intracellular pools disrupt its uptake after drug treatment. This can be overcome by using cross-labeled 13C-stearate from [1,2- 13C2]-d-glucose as the internal tracer and the independent explanatory variable to study associations among markers of rosiglitazone-induced stearate breakdown in a single [1,2-13C2]-d-glucose tracer experiment during drug efficacy testing in cultured cells.",
keywords = "2-13C2]-d-Glucose [U-13C18]-stearate, EZTopolome [1, Liver cancer, SWAS, System-wide association study, Targeted tracer fate association study, TTFAS",
author = "Boros, {L{\'a}szl{\'o} G.} and Beger, {Richard D.} and Meuillet, {Emmanuelle J.} and Colca, {Jerry R.} and S{\'a}ndor Szalma and Thompson, {Patricia A.} and L. Dux and Gyula Farkas and G{\'a}bor Somlyai",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-7091-1824-5_15",
language = "English",
isbn = "9783709118245",
pages = "349--372",
booktitle = "Tumor Cell Metabolism: Pathways, Regulation and Biology",
publisher = "Springer-Verlag Vienna",

}

TY - CHAP

T1 - Targeted 13C-labeled tracer fate associations for drug efficacy testing in cancer

AU - Boros, László G.

AU - Beger, Richard D.

AU - Meuillet, Emmanuelle J.

AU - Colca, Jerry R.

AU - Szalma, Sándor

AU - Thompson, Patricia A.

AU - Dux, L.

AU - Farkas, Gyula

AU - Somlyai, Gábor

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Metabolomics technologies continue to develop not only to study endpoint steady-state concentrations of numerous metabolites in normal and cancer cells but also to examine metabolic flux and networks. These techniques are of importance for understanding tumor cell metabolism and for the development of new drugs and treatment strategies. The choice of tracer substrates is central as 13C-labeled substrates readily improve real-time reaction visibility by increasing metabolic network transparencies in cancer metabolomics. In this chapter, targeted [1,2- 13C2]-d-glucose single tracer fate associations are compared with the external [U- 13C18]-stearate oxidation model for thiazolidinedione efficacy testing in primary liver tumor cells. Although the externally supplied [U- 13C18]-stearate tracer readily labels multiple products by acetyl-CoA exchange, parallel stearate synthesis and mobilization from unlabeled intracellular pools disrupt its uptake after drug treatment. This can be overcome by using cross-labeled 13C-stearate from [1,2- 13C2]-d-glucose as the internal tracer and the independent explanatory variable to study associations among markers of rosiglitazone-induced stearate breakdown in a single [1,2-13C2]-d-glucose tracer experiment during drug efficacy testing in cultured cells.

AB - Metabolomics technologies continue to develop not only to study endpoint steady-state concentrations of numerous metabolites in normal and cancer cells but also to examine metabolic flux and networks. These techniques are of importance for understanding tumor cell metabolism and for the development of new drugs and treatment strategies. The choice of tracer substrates is central as 13C-labeled substrates readily improve real-time reaction visibility by increasing metabolic network transparencies in cancer metabolomics. In this chapter, targeted [1,2- 13C2]-d-glucose single tracer fate associations are compared with the external [U- 13C18]-stearate oxidation model for thiazolidinedione efficacy testing in primary liver tumor cells. Although the externally supplied [U- 13C18]-stearate tracer readily labels multiple products by acetyl-CoA exchange, parallel stearate synthesis and mobilization from unlabeled intracellular pools disrupt its uptake after drug treatment. This can be overcome by using cross-labeled 13C-stearate from [1,2- 13C2]-d-glucose as the internal tracer and the independent explanatory variable to study associations among markers of rosiglitazone-induced stearate breakdown in a single [1,2-13C2]-d-glucose tracer experiment during drug efficacy testing in cultured cells.

KW - 2-13C2]-d-Glucose [U-13C18]-stearate

KW - EZTopolome [1

KW - Liver cancer

KW - SWAS

KW - System-wide association study

KW - Targeted tracer fate association study

KW - TTFAS

UR - http://www.scopus.com/inward/record.url?scp=84948732953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948732953&partnerID=8YFLogxK

U2 - 10.1007/978-3-7091-1824-5_15

DO - 10.1007/978-3-7091-1824-5_15

M3 - Chapter

SN - 9783709118245

SN - 9783709118238

SP - 349

EP - 372

BT - Tumor Cell Metabolism: Pathways, Regulation and Biology

PB - Springer-Verlag Vienna

ER -